The authors of the article conclude that the Pfizer BioNTech vaccine is effective against the new strains of the coronavirus. Among participants 60 years of age or older, the rate of Covid-19associated death in the booster group was lower than in the nonbooster group by a factor of 14.7 (95 CI, 10.0 to 21.4). ![]() Scientists note that the results of the study generally coincide with the data obtained during clinical trials. The study did not find a decrease in the effectiveness of the vaccination for people over the age of 70. ![]() The estimated efficacy at preventing death from COVID-19 was 72% two weeks after the first dose. Correspondence from The New England Journal of Medicine Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. The risk of hospitalisation was reduced by 74% at day 14-20 and 87% one week after first dose - the likelihood of severe disease was also decreased, by 62% and 92% respectively. ![]() The article was published in the New England Journal of Medicine. These findings indicate that immunity against the delta variant of SARS-CoV-2 waned in all age groups a few months after receipt of the second dose of vaccine.Ĭopyright © 2021 Massachusetts Medical Society.The COVID-19 vaccine developed and produced by Pfizer and BioNTech has shown 94% efficacy following the vaccination of more than 590,000 people in Israel, according to a study published in The New England Journal of Medicine.Īccording to the study at day 14 through 20 after the first dose the vaccine was 57% effective at preventing symptomatic infection, one week after the second dose the protection rose to 94%. The peer-reviewed study, parts of which have been reported previously, was published Wednesday in the New England Journal of Medicine. Israel National Center for Trauma & Emergency Medicine Research > Israeli. The rate ratio for severe disease among persons fully vaccinated in the month when they were first eligible, as compared with those fully vaccinated in March, was 1.8 (95% CI, 1.1 to 2.9) among persons 60 years of age or older and 2.2 (95% CI, 0.6 to 7.7) among those 40 to 59 years of age owing to small numbers, the rate ratio could not be calculated among persons 16 to 39 years of age. Among persons 16 to 39 years of age, the rate ratio for infection among those fully vaccinated in March (when they were first eligible), as compared with 2 months later, in May, was 1.6 (95% CI, 1.3 to 2.0). Among persons 40 to 59 years of age, the rate ratio for infection among those fully vaccinated in February (when they were first eligible), as compared with 2 months later, in April, was 1.7 (95% CI, 1.4 to 2.1). The new england journal of medicine years. We used a Poisson regression model to compare rates of confirmed SARS-CoV-2 infection and severe Covid-19 among persons vaccinated during different time periods, with stratification according to age group and with adjustment for possible confounding factors.Īmong persons 60 years of age or older, the rate of infection in the July 11-31 period was higher among persons who became fully vaccinated in January 2021 (when they were first eligible) than among those fully vaccinated 2 months later, in March (rate ratio, 1.6 95% confidence interval, 1.3 to 2.0). 2 (delta) variant of SARS-CoV-2 became the dominant strain in Israel (Fig. Dov has published in the New England Journal of Medicine, Health Affairs, The Milbank Quarterly, and other major scientific journals. We used data on confirmed infection and severe disease collected from an Israeli national database for the period of July 11 to 31, 2021, for all Israeli residents who had been fully vaccinated before June 2021. Bank of Israel Contributing to the prosperity of Israel and the welfare of its citizens In the headlines Representative exchange rates Power BI Report The. The extent of waning immunity of the vaccine against the delta variant in Israel is unclear. Possible reasons for the resurgence were reduced vaccine effectiveness against the delta (B.1.617.2) variant and waning immunity. After a period with almost no cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, a resurgent Covid-19 outbreak began in mid-June 2021. In December 2020, Israel began a mass vaccination campaign against coronavirus disease 2019 (Covid-19) by administering the BNT162b2 vaccine, which led to a sharp curtailing of the outbreak.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |